CSF1R and graft versus host disease: Recently, Wolff et al. published the results of a phase II clinical trial of axatilimab, an inhibitory antibody targeting the CSF1R, in patients with multiorgan fibrosis secondary to graft-versus-host disease (GVHD) refractory to other therapies (4).